Correlation Between Day One and Inozyme Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Day One and Inozyme Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Day One and Inozyme Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Day One Biopharmaceuticals and Inozyme Pharma, you can compare the effects of market volatilities on Day One and Inozyme Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Day One with a short position of Inozyme Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Day One and Inozyme Pharma.

Diversification Opportunities for Day One and Inozyme Pharma

0.76
  Correlation Coefficient

Poor diversification

The 3 months correlation between Day and Inozyme is 0.76. Overlapping area represents the amount of risk that can be diversified away by holding Day One Biopharmaceuticals and Inozyme Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inozyme Pharma and Day One is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Day One Biopharmaceuticals are associated (or correlated) with Inozyme Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inozyme Pharma has no effect on the direction of Day One i.e., Day One and Inozyme Pharma go up and down completely randomly.

Pair Corralation between Day One and Inozyme Pharma

Given the investment horizon of 90 days Day One Biopharmaceuticals is expected to under-perform the Inozyme Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Day One Biopharmaceuticals is 1.37 times less risky than Inozyme Pharma. The stock trades about -0.01 of its potential returns per unit of risk. The Inozyme Pharma is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  226.00  in Inozyme Pharma on October 20, 2024 and sell it today you would lose (90.00) from holding Inozyme Pharma or give up 39.82% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy99.8%
ValuesDaily Returns

Day One Biopharmaceuticals  vs.  Inozyme Pharma

 Performance 
       Timeline  
Day One Biopharmaceu 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Day One Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Inozyme Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Day One and Inozyme Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Day One and Inozyme Pharma

The main advantage of trading using opposite Day One and Inozyme Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Day One position performs unexpectedly, Inozyme Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inozyme Pharma will offset losses from the drop in Inozyme Pharma's long position.
The idea behind Day One Biopharmaceuticals and Inozyme Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Complementary Tools

Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Commodity Directory
Find actively traded commodities issued by global exchanges